Drug Shortage Report for CAPRELSA
Report ID | 155030 |
Drug Identification Number | 02378582 |
Brand name | CAPRELSA |
Common or Proper name | Caprelsa |
Company Name | SANOFI-AVENTIS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | VANDETANIB |
Strength(s) | 100MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | L01XE |
ATC description | OTHER ANTINEOPLASTIC AGENTS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2022-12-01 |
Actual start date | |
Estimated end date | 2023-04-28 |
Actual end date | 2022-06-30 |
Shortage status | Avoided shortage |
Updated date | 2022-06-30 |
Company comments | Manufacturing change. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v10 | 2022-06-30 | French | Compare |
v9 | 2022-06-30 | English | Compare |
v8 | 2022-06-27 | French | Compare |
v7 | 2022-06-27 | English | Compare |
v6 | 2022-06-15 | French | Compare |
v5 | 2022-06-15 | English | Compare |
v4 | 2022-04-08 | French | Compare |
v3 | 2022-04-08 | English | Compare |
v2 | 2022-02-15 | French | Compare |
v1 | 2022-02-15 | English | Compare |
Showing 1 to 10 of 10